Vertex Pharmaceuticals Incorporated Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share. Vertex has granted the underwriters an option to purchase up to an additional 900,000 shares of Vertex common stock on the same terms and conditions to cover over-allotments, if any.